SREBF1 and metabolic dysfunction-associated steatotic liver disease: As illustrated in Figures 2(a)–2(c), the expressions of PPAR-γ and SREBP-1 and its downstream protein FASN were increased in NAFLD mice when compared with control group, whereas administration of high-dose MV significantly reduced the expression of these proteins.